28 Jul 2016 16:22
Â
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Â
This announcement contains inside information.
Â
Motif Bio plc
("Motif Bio" or the "Company")
28 July 2016
Â
MOTIF BIO FILES PRELIMINARY PROSPECTUS FOR PROPOSED U.S. PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND APPLIES FOR NASDAQ LISTING
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that, further to the notification on 13 July 2016 of the filing of a registration statement with the United States Securities and Exchange Commission (the "SEC") relating to a proposed public offering of American Depositary Shares ("ADSs") and listing of ADSs on the NASDAQ Global Select Market, the Company has filed an amended registration statement with the SEC, which includes a preliminary prospectus for the proposed offering.
SunTrust Robinson Humphrey, Inc. and Ladenburg Thalmann & Co. Inc. are acting as the book-running managers for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from SunTrust Robinson Humphrey, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; Email: strh.prospectus@suntrust.com; Telephone: 404-926-5744; or fax: 404-926-5464.
Â
Â
For further information please contact:
Â
Motif Bio plc Richard Morgan (Chairman) Graham Lumsden (Chief Executive Officer)  | info@motifbio.com  |
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson  | +44 (0)20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) Â | +44 (0)20 3861 6625 |
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort | +44 (0)20 7933 8780 or motifbio@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002 |
MC Services AG (EUROPEAN IR) | |
Raimund Gabriel | +49 (0)89 210 2280 |
Â
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to complete in the second half of 2017.